Healthcare Sector
Market Tracker
15m Chart - Support and Resistance levels are based on the large dark pool & equity prints at the plotted levels. Displays strongest levels above and below the spot price.
Represents the strikes that had the highest premium of whale flow (on the ASK side) over the past 5 trading days.
Represents the strikes that had the highest premium of whale flow (on the BID side) over the past 5 trading days.
Represents the largest cumulative premium levels above and below the current spot price. The price in the pink bubble represents the spot price.
Total Open Interest of Calls & Puts across all strikes and expirations over the past 16 trading days.
Expires | Type | Strike | OI | Change | Percent |
---|---|---|---|---|---|
08/15/2025 | CALL | $7.50 | 10 | +5 | +100.00% |
01/17/2025 | CALL | $2.50 | 0 | 0 | |
01/17/2025 | CALL | $5.00 | 44 | 0 | |
01/17/2025 | CALL | $7.50 | 0 | 0 | |
01/17/2025 | CALL | $10.00 | 0 | 0 | |
01/17/2025 | PUT | $2.50 | 220 | 0 | |
05/16/2025 | PUT | $10.00 | 2 | 0 | |
08/15/2025 | CALL | $2.50 | 34 | 0 | |
08/15/2025 | CALL | $5.00 | 20 | 0 | |
08/15/2025 | PUT | $2.50 | 0 | 0 | |
08/15/2025 | PUT | $5.00 | 5 | 0 | |
08/15/2025 | PUT | $7.50 | 0 | 0 |
Contracts with largest changes in open interest from the previous trading day to the current/most recent.
Name | Pct Held | Shares | Total |
---|---|---|---|
Vanguard Total Stock Market Index Fund | 3.34% | 460k | 634.8k |
Vanguard Extended Market Index Fund | 1.46% | 201.26k | 277.74k |
Fidelity Extended Market Index Fund | 0.55% | 75.45k | 104.12k |
iShares Micro Cap ETF | 0.17% | 22.83k | 31.51k |
Fidelity Total Market Index Fund | 0.13% | 18.47k | 25.48k |
Fidelity Series Total Market Index Fund | 0.12% | 16.81k | 23.2k |
Vanguard Institutional Index-Inst Total Stock Market Ind | 0.10% | 13.26k | 18.3k |
Fidelity NASDAQ Composite Index Fund | 0.08% | 10.48k | 14.46k |
DFA U.S. Core Equity 2 Portfolio | 0.04% | 5.08k | 7.01k |
DFA U.S. Vector Equity Portfolio | 0.03% | 4.11k | 5.67k |
4 High-Risk, High-Reward Small-Cap Stocks to Play the Rotation - Investing.com
07/24 08:36 am
Investing.com
Read moreAre Medical Stocks Lagging DaVita (DVA) This Year?
06/26 09:40 am
Zacks Investment Research
Read moreEledon Presents Updated Data from Ongoing Phase 1b Trial Evaluating Tegoprubart for Prevention of Rejection in Kidney Transplantation
06/03 04:01 pm
GlobeNewswire Inc.
Read moreEledon Pharmaceuticals (ELDN) Could Find a Support Soon, Here's Why You Should Buy the Stock Now
05/27 09:55 am
Zacks Investment Research
Read moreEledon Pharmaceuticals, Inc. (ELDN) is a Great Momentum Stock: Should You Buy?
05/22 12:00 pm
Zacks Investment Research
Read moreEledon Pharmaceuticals (ELDN) Moves to Buy: Rationale Behind the Upgrade
05/14 12:00 pm
Zacks Investment Research
Read moreEledon Pharmaceuticals Reports First Quarter 2024 Operating and Financial Results
05/09 07:30 am
GlobeNewswire Inc.
Read moreNano-Cap Eledon Pharmaceuticals' Investigational Drug Shows Safety In Early Organ Transplant Study, Analyst Boosts Forecast On Increased Confidence
05/07 03:40 pm
Benzinga
Read moreEledon Announces Clinical Progress with Tegoprubart in the Prevention of Transplant Rejection
05/07 07:05 am
GlobeNewswire Inc.
Read moreEledon Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Operating and Financial Results
03/28 04:01 pm
GlobeNewswire Inc.
Read moreEledon Pharmaceuticals Announces 12th Participant Enrolled in Phase 2 BESTOW Trial Evaluating Tegoprubart for the Prevention of Organ Rejection
03/25 04:56 pm
GlobeNewswire Inc.
Read moreEledon Pharmaceuticals Announces Use of Tegoprubart in First-ever Transplant of Genetically Modified Kidney from a Pig to a Human
03/21 10:31 am
GlobeNewswire Inc.
Read moreEledon Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
02/13 08:01 pm
GlobeNewswire Inc.
Read moreEledon Pharmaceuticals Highlights Recent Business Milestones and Provides 2024 Outlook
01/04 05:40 pm
GlobeNewswire Inc.
Read moreEledon Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
12/04 07:00 pm
GlobeNewswire Inc.
Read moreEledon Pharmaceuticals to Present at Noble Capital Markets' Emerging Growth Equity Conference
11/29 05:05 pm
GlobeNewswire Inc.
Read moreExpert Ratings for Eledon Pharma
11/13 11:00 am
Benzinga
Read moreEledon Pharmaceuticals Reports Third Quarter 2023 Operating and Financial Results
11/09 05:01 pm
GlobeNewswire Inc.
Read moreEledon Pharmaceuticals, Inc. (ELDN) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?
11/09 10:55 am
Zacks Investment Research
Read moreEledon Pharmaceuticals to Present at Jefferies London Healthcare Conference
11/08 05:05 pm
GlobeNewswire Inc.
Read moreEledon Reports Updated Data from Ongoing Phase 1b Trial Evaluating Tegoprubart for Prevention of Rejection in Kidney Transplantation
11/02 09:05 am
GlobeNewswire Inc.
Read moreEledon Pharmaceuticals Strengthens Leadership Team with Appointment of Eliezer Katz, M.D., FACS as Chief Medical Officer
10/23 07:00 am
GlobeNewswire Inc.
Read moreEledon Pharmaceuticals to Present Data from Ongoing Phase 1b Trial of Tegoprubart in Patients Undergoing Kidney Transplantation at the American Society of Nephrology Kidney Week 2023 Annual Meeting
10/13 07:00 am
GlobeNewswire Inc.
Read moreEledon Pharmaceuticals Appoints Kidney Transplant Specialist Dr. Allan Douglas Kirk to Board of Directors
10/02 07:00 am
GlobeNewswire Inc.
Read moreBenzinga's Top Ratings Upgrades, Downgrades For September 27, 2023
09/27 11:00 am
Benzinga
Read moreEledon Pharmaceuticals Announces Use of Tegoprubart anti-CD40L Antibody in Second-ever Transplant of Genetically Modified Heart from a Pig to a Human
09/25 07:00 am
GlobeNewswire Inc.
Read moreEledon Pharmaceuticals to Participate at the 2023 Cantor Fitzgerald Global Healthcare Conference
09/20 04:05 pm
GlobeNewswire Inc.
Read moreEledon Pharmaceuticals Appoints Industry Veteran James Robinson to its Board of Directors
09/11 07:00 am
GlobeNewswire Inc.
Read moreEledon Pharmaceuticals to Present at Jefferies Healthcare Conference
06/02 08:00 am
GlobeNewswire Inc.
Read moreEledon Reports Data from Ongoing Phase 1b Trial Evaluating Tegoprubart in Patients Undergoing Kidney Transplantation at World Congress of Nephrology
03/31 06:00 am
GlobeNewswire Inc.
Read moreEledon Pharmaceuticals Reports Fourth Quarter and Full-Year 2022 Operating and Financial Results
03/30 04:01 pm
GlobeNewswire Inc.
Read moreEledon Pharmaceuticals to Report Fourth Quarter and Full Year 2022 Financial Results on Thursday, March 30, 2023
03/23 04:05 pm
GlobeNewswire Inc.
Read moreEledon Pharmaceuticals to Present at SVB Securities Global Biopharma Conference
02/08 05:05 pm
GlobeNewswire Inc.
Read moreEledon Pharmaceuticals Provides Business and Pipeline Updates
01/09 09:31 am
GlobeNewswire Inc.
Read moreC-Path's Transplant Therapeutics Consortium Receives EMA Qualification Opinion for iBox Scoring System
12/21 05:05 pm
GlobeNewswire Inc.
Read moreEledon Pharmaceuticals to Report Third Quarter 2022 Financial Results on Monday, November 14, 2022
11/03 04:05 pm
GlobeNewswire Inc.
Read moreEledon Pharmaceuticals Announces Upcoming Presentations at ASN’s Kidney Week 2022 and NEALS
10/24 04:05 pm
GlobeNewswire Inc.
Read moreEledon Pharmaceuticals to Present at Ladenburg Thalmann Healthcare Conference
09/22 04:05 pm
GlobeNewswire Inc.
Read moreEledon Pharmaceuticals Receives FDA Clearance of IND Application to Evaluate Tegoprubart for the Prevention of Rejection in Kidney Transplant Recipients
08/01 05:00 am
GlobeNewswire Inc.
Read moreEledon Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
06/10 04:05 pm
GlobeNewswire Inc.
Read morePenny Stocks To Buy Now? 4 To Watch This Week
05/31 09:49 am
PennyStocks
Read moreEledon Announces Positive Topline Results from Phase 2a Trial of Tegoprubart Demonstrating Safety, Target Engagement, and Biomarker Response in Patients Living with Amyotrophic Lateral Sclerosis
05/31 06:00 am
GlobeNewswire Inc.
Read moreEledon Pharmaceuticals to Report First Quarter 2022 Financial Results on Thursday, May 12, 2022
05/05 04:05 pm
GlobeNewswire Inc.
Read moreEledon Pharmaceuticals to Participate in 18th Annual Noble Capital Markets Investor Conference
04/18 04:05 pm
GlobeNewswire Inc.
Read moreEledon to Host Virtual R&D Day on Thursday, April 28, 2022
04/14 04:05 pm
GlobeNewswire Inc.
Read moreEledon Pharmaceuticals Reports Fourth Quarter and Full-Year 2021 Operating and Financial Results
03/24 04:01 pm
GlobeNewswire Inc.
Read moreThe Daily Biotech Pulse: Novartis Prostate Cancer Drug Lands FDA Approval, Ligand Announces SPAC Deal To Spin Off Antibody Business, Lilly's Lung Cancer Therapy Hit With CRL
03/24 08:10 am
Benzinga
Read moreEledon Pharmaceuticals to Participate in 11th Annual SVB Leerink Global Healthcare Conference
02/08 05:05 pm
GlobeNewswire Inc.
Read moreEledon Pharmaceuticals to Participate in January 2022 Investor Conferences
12/27 06:17 pm
GlobeNewswire Inc.
Read more